Project Grant R01CA285856
Award Date
7/2/24
Completion Date
6/30/29
Dollars Obligated
$583K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research aimed at investigating the use of SMARCA2 degraders as a therapeutic approach for lung cancers with SMARCA4 deficiencies. The $557,418 grant, with a project period from March 2025 to February 2030, will be conducted by The Trustees of Columbia University in the City of New York. The key objectives are to: 1) assess the effects of SMARCA2...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine will support a comprehensive research program aimed at understanding and disrupting the adeno-to-squamous transition (AST) observed in non-small cell lung cancer (NSCLC) patients treated with KRAS inhibitor drugs. The $703,410 award, effective January 16, 2025 through December 31, 2029, will fund investigations to identify chromatin regulators that drive...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $267,527 to The University of Texas MD Anderson Cancer Center to investigate methods to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors. The key research objectives are to: 1) examine the mechanism of resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors; 2) develop SMARCA2 degrading molecules as potential therapies to overcome this resistance; 3)...
This Project Grant award of $730,400.00 from the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program supports research by the Sloan-Kettering Institute for Cancer Research to investigate the role of metabolic pathways in driving lung adenocarcinoma (LUAD) progression and treatment resistance. The key objectives are to determine how specific configurations of the tricarboxylic acid (TCA) cycle support different LUAD cell states, identify the TCA cycle outputs...
This federal Project Grant award of $230,010 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to investigate the underlying mechanisms driving the aggressive metastasis of small cell lung cancer (SCLC). The project utilizes innovative methods including human pluripotent stem cell-derived pulmonary neuroendocrine cells, clinical samples, patient-derived xenografts, and advanced technologies such as single-cell sequencing and...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
This Project Grant award of $1,480,500 from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is aimed at developing a comprehensive, spatiotemporally-resolved roadmap of small cell lung cancer (SCLC) metastasis. The research, conducted by the Trustees of Columbia University in the City of New York, will seek to elucidate the cell intrinsic and extrinsic mechanisms underlying SCLC metastasis using a genetically engineered...
The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant supports a 5-year research project to develop multimodal predictive models that integrate real-world data from circulating tumor DNA sequencing, tumor genomics, medical imaging, and clinical notes to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The research aims...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $3,787,956.00 in funding to New York University School of Medicine to investigate and target replication stress in small cell lung cancer (SCLC). The research aims to understand the role of the SLFN11 gene in regulating chemotherapy sensitivity in SCLC subtypes, study how different replication stress response pathways and modulators impact chemosensitivity, and develop strategies to...
The federal Project Grant award of $489,527 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research by Emory University to enhance the understanding of genetic variants in the SMARCB1 gene and their impact on cancer biology. Specifically, the project will perform deep mutagenesis scanning of SMARCB1 to assess over 99% of genetic mutations, with the goal of elucidating key mutations and residues that influence SMARCB1's...